covid-19

The Health Sciences Authority (HSA) has authorised Pfizer’s Comirnaty COVID-19 vaccine on 28 September 2022, for the prevention of Coronavirus Disease 2019 (COVID-19) in children aged 6 months through 4…

The Health Sciences Authority (HSA) has granted interim authorisation under the Pandemic Special Access Route (PSAR) for Spikevax Bivalent Original/Omicron COVID-19 vaccine by Moderna on 14 September 2022. It comprises…

Singapore’s Health Sciences Authority (HSA) has extended the authorisation of Moderna’s Spikevax¹ COVID-19 vaccine via the Pandemic Special Access Route (PSAR) on 24 August 2022, for the prevention of Coronavirus…

The Health Sciences Authority (HSA), in consultation with its Medicines Advisory Committee, has, on 1 August 2022, granted an interim authorisation under the Pandemic Special Access Route (PSAR) for AstraZeneca’s…

The Health Sciences Authority (HSA), in consultation with its Medicines Advisory Committee, has granted interim authorisation under the Pandemic Special Access Route (PSAR) for MSD’s LAGEVRIO (molnupiravir) on 19 April…

Regulatory authorities of China have approved the mixing of domestic inactivated vaccines against COVID (in particular, Sinovac and Sinopharm) and use of a different vaccine, including adenoviral-based, as booster shot…

The Health Sciences Authority (HSA) had granted an interim authorisation under the Pandemic Special Access Route (PSAR) for Nuvaxovid COVID-19 vaccine (Nuvaxovid) by Novavax to be used in Singapore for…